Skip to main content
. 2020 Dec 3;2020(12):CD013020. doi: 10.1002/14651858.CD013020.pub2

Abetz 2006.

Study characteristics
Methods Recruitment period:

  • not reported


Outcomes:

  • pain response


Pain assessment tool:

  • Brief Pain Inventory (BPI): pain severity scale score, pain interference scale score (McGill Pain Questionnaire)


Randomization:

  • intervention vs control
Participants Eligibility criteria:

  • not reported


Exclusion criteria:

  • not reported


Participants randomized:

  • 402 randomized, 201 zoledronic acid, 201 placebo


Mean age:

  • not reported


Country of participants:

  • not reported
Interventions Previous interventions:

  • not reported


Interventions during study period:

  • intervention: zoledronic acid 4 mg

  • control: placebo
Outcomes Reported and analyzed in this review:

  • pain response (pain at its worst, pain at its least, pain on average, pain right now)
Funding sources Funding sources:

  • not reported
Declarations of interest Conflicts of interest: see meeting.ascopubs.org/cgi/content/abstract/24/18 suppl/4638?sid=2d509f53‐6021‐4c00‐8de9‐6bbec9c7cf92

  • authors were employed at Novartis, received honoraria from Novartis, or were consultants of Novartis
Notes Only abstracts available, insufficient reporting on methods.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence generation (selection bias) Unclear risk No information on sequence generation
Allocation concealment (selection bias) Unclear risk No information on allocation concealment
Blinding of participants and personnel (performance bias)
Blinding of participants Unclear risk Placebo‐controlled trial, but no information about blinding of participants or personnel
Blinding of participants and personnel (performance bias)
Blinding of personnel Unclear risk Placebo‐controlled trial, but no information about blinding of participants or personnel
Blinding of outcome assessment (detection bias)
Outcomes subjective to participants Unclear risk Insufficient information on blinding of outcome assessment
Incomplete outcome data (attrition bias)
Patient‐reported outcomes (other than safety data) Unclear risk "Post‐baseline missing data was replaced by Last Observation Carried Forward (LOCF)"; insufficient information regarding discontinuations and intention‐to‐treat
Incomplete outcome data (attrition bias)
Other outcomes Unclear risk No reporting on outcomes other than patient‐reported outcomes. Insufficient information regarding discontinuations and ITT
Selective reporting (reporting bias) Unclear risk No study protocol available.
Other bias High risk Insufficient reporting on methods